TY - JOUR
T1 - An essential dose of cisplatin for super-selective intra-arterial infusion concomitant with radiotherapy in patient with maxillary squamous cell carcinoma
AU - Kanazawa, Yuji
AU - Shojaku, Hideo
AU - Takakura, Hiromasa
AU - Fujisaka, Michiro
AU - Tachino, Hirohiko
AU - Watanabe, Yukio
AU - Tomizawa, Gakuto
AU - Kawabe, Hideto
AU - Shojaku, Hiroko
AU - Seto, Hikaru
AU - Otani, Kyoko
AU - Fukuoka, Jyunya
PY - 2012/8
Y1 - 2012/8
N2 - The present study investigated the efficacy and safety of using a lower dose of cisplatin (CDDP) in superselective intra-arterial concurrent chemoradiotherapy (SSIACRT) to treat maxillary squamous cell carcinoma. 10 patients with maxillary squamous cell carcinoma (T3 n = 6, T4a n = 4) without regional or distant metastasis were treated by SSIACRT. The CDDP dose per course was 100 mg/body, i.e. 50-80 mg/m2. 6-9 weeks after SSIACRT, partial maxillectomy was performed on all patients. Clinical and histological responses, survival rates, and adverse events were investigated. 10 (100%) of 10 patients achieved both clinical and pathological complete or partial remission. The 3-year overall and disease-free survival rates were 100 and 90%, respectively. Grade 3 toxicity was experienced by two patients. In conclusion, the SSIACRT regimen with a lower dose of CDDP (100 mg/ body) had an equivalent therapeutic outcome and lower toxic outcome compared to a higher dose of CDDP. This regimen could be an effective and safe therapeutic modality for maxillary squamous cell carcinoma except T4b and N1/2 disease.
AB - The present study investigated the efficacy and safety of using a lower dose of cisplatin (CDDP) in superselective intra-arterial concurrent chemoradiotherapy (SSIACRT) to treat maxillary squamous cell carcinoma. 10 patients with maxillary squamous cell carcinoma (T3 n = 6, T4a n = 4) without regional or distant metastasis were treated by SSIACRT. The CDDP dose per course was 100 mg/body, i.e. 50-80 mg/m2. 6-9 weeks after SSIACRT, partial maxillectomy was performed on all patients. Clinical and histological responses, survival rates, and adverse events were investigated. 10 (100%) of 10 patients achieved both clinical and pathological complete or partial remission. The 3-year overall and disease-free survival rates were 100 and 90%, respectively. Grade 3 toxicity was experienced by two patients. In conclusion, the SSIACRT regimen with a lower dose of CDDP (100 mg/ body) had an equivalent therapeutic outcome and lower toxic outcome compared to a higher dose of CDDP. This regimen could be an effective and safe therapeutic modality for maxillary squamous cell carcinoma except T4b and N1/2 disease.
KW - Cisplatin
KW - Concurrent chemoradiotherapy
KW - Dose
KW - Maxillary squamous cell carcinoma
KW - Super-selective intra-arterial administration
UR - http://www.scopus.com/inward/record.url?scp=84864988707&partnerID=8YFLogxK
U2 - 10.1007/s00405-011-1857-7
DO - 10.1007/s00405-011-1857-7
M3 - 学術論文
C2 - 22146863
AN - SCOPUS:84864988707
SN - 0937-4477
VL - 269
SP - 1985
EP - 1991
JO - European Archives of Oto-Rhino-Laryngology
JF - European Archives of Oto-Rhino-Laryngology
IS - 8
ER -